| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:10746934 | IVR | 100 mg/kg | 100 mg/kg | Exhibit sexual dimorphism | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 100 mg/kg | 100 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Exhibit sexual dimorphism | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Exhibit sexual dimorphism | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Exhibit sexual dimorphism | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | - | No significant effects observed | - | |
| PMID:12460804 | IVTH | 0.000025 - 0.00005 M | 0.00005 M | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations |
| PMID:12858341 | IVTH | 0.000001 M | 0.000001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.000001 M | 0.000001 M | Affects placental differentiation | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:15372139 | IVR | 0.1 mg/kg | 0.1 mg/kg | Affects testosterone metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 100 mg/kg | 100 mg/kg | Affects testosterone metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Affects testosterone metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Affects testosterone metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:16732769 | IVR | 50 mg/L | 50 mg/L | Decreased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVR | 50 mg/L | 50 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 350 mg/L | 350 mg/L | Increased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 350 mg/L | 350 mg/L | Increased weights of adrenal gland in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 350 mg/L | 350 mg/L | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 350 mg/L | 350 mg/L | Alterations in preputial separation | Reproductive endocrine-mediated perturbations | |
| IVR | 350 mg/L | 350 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 350 mg/L | 350 mg/L | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/L | - | No significant effects observed | - | |
| PMID:17683461 | IVR | 35 mg/kg | 35 mg/kg | Undescended testes (or cryptorchidism) | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:19214582 | IVTH | 10 mU/mL | 10 mU/mL | Affects thyroid function | Metabolic endocrine-mediated perturbations |
| PMID:20830510 | IVR | 50 mg/kg/day | 50 mg/kg/day | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations |
| PMID:22403704 | IVTH | 0.00001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.00001 M | 0.00001 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| PMID:24824690 | IVR | 1.89 mg/kg | 1.89 mg/kg | Increase in T4 levels | Metabolic endocrine-mediated perturbations |
| IVR | 1.89 mg/kg | 1.89 mg/kg | Increase in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1.89 mg/kg | 1.89 mg/kg | Decrease in TSH levels | Metabolic endocrine-mediated perturbations | |
| PMID:25014179 | IVTH | 0.0000000001 - 0.00001 M | 0.00000001 - 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:25552505 | IVR | 1.89 mg/kg/day | 1.89 mg/kg/day | Increase in T3 levels | Metabolic endocrine-mediated perturbations |
| IVR | 1.89 mg/kg/day | 1.89 mg/kg/day | Increase in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 7.77 mg/kg/day | 7.77 mg/kg/day | Increase in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 7.77 mg/kg/day | 7.77 mg/kg/day | Increase in T4 levels | Metabolic endocrine-mediated perturbations | |
| PMID:25682698 | IVTH | 0.000001 - 0.00001 M | 0.000001 - 0.00001 M | Affects androgen signaling | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000001 - 0.00001 M | 0.000001 - 0.00001 M | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| PMID:26621281 | IVR | 0.002 mg/kg | 0.002 mg/kg | Affects iodine uptake into thyroid | Metabolic endocrine-mediated perturbations |
| IVR | 0.002 mg/kg | 0.002 mg/kg | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| PMID:26928317 | IVR | 35 mg/kg | 35 mg/kg | Affects testicular morphology | Reproductive endocrine-mediated perturbations |
| PMID:26977256 | IVR | 50 mg/L | 50 mg/L | Affects liver function | Hepatic endocrine-mediated perturbations |
| IVR | 50 mg/L | 50 mg/L | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 500 mg/L | 500 mg/L | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 500 mg/L | 500 mg/L | Affects liver function | Hepatic endocrine-mediated perturbations | |
| IVR | 160 mg/L | 160 mg/L | Affects liver function | Hepatic endocrine-mediated perturbations | |
| IVR | 160 mg/L | 160 mg/L | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 5 mg/L | 5 mg/L | Affects liver function | Hepatic endocrine-mediated perturbations | |
| IVR | 5 mg/L | 5 mg/L | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| PMID:27905040 | IVR | 0.02 mg/L | 0.02 mg/L | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
| IVR | 0.02 mg/L | 0.02 mg/L | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.02 mg/L | 0.02 mg/L | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| PMID:28263910 | IVR | 10 mg/kg | 10 mg/kg | Affects the normal functioning of reproductive system | Reproductive endocrine-mediated perturbations |
| IVR | 10 mg/kg | 10 mg/kg | Affects social behavior | Neurological endocrine-mediated perturbations | |
| PMID:28361414 | IVR | 0.02 mg/L | 0.02 mg/L | Affects thyroid function | Metabolic endocrine-mediated perturbations |
| IVR | 0.02 mg/L | 0.02 mg/L | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| PMID:28853094 | IVR | 0.02 mg/L | 0.02 mg/L | Decreased levels of norepinephrine | Neurological endocrine-mediated perturbations |
| IVR | 0.02 mg/L | 0.02 mg/L | Decreased levels of epinephrine | Neurological endocrine-mediated perturbations | |
| PMID:28862600 | IVR | 0.02 mg/L | 0.02 mg/L | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.02 mg/L | 0.02 mg/L | Increased 17-OH-progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/L | 0.02 mg/L | Increase in corticosterone levels | Neurological endocrine-mediated perturbations | |
| IVR | 0.02 mg/L | 0.02 mg/L | Decreased aldosterone levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.02 mg/L | 0.02 mg/L | Changes in adrenal gland morphology | Metabolic endocrine-mediated perturbations | |
| IVR | 0.02 mg/L | 0.02 mg/L | Decreased androstenedione levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/L | 0.02 mg/L | Decreased Dehydroepiandrosterone (DHEA) levels | Metabolic endocrine-mediated perturbations | |
| PMID:30817981 | IVTH | 0.00005 M | 0.00005 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00005 M | 0.00005 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:31350654 | IVR | 0.02 mg/L | 0.02 mg/L | Affects development of adrenal gland | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations |
| IVR | 0.02 mg/L | 0.02 mg/L | Changes in adrenal gland morphology | Metabolic endocrine-mediated perturbations | |
| PMID:9168009 | IVTH | 0.00001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.